Trial Profile
A 54-week Follow-Up to: A Phase III, Multicenter, Double-Blind, Randomized, Placebo -Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-0431A (A Fixed-Dose Combination Tablet of Sitagliptin and Metformin) in Pediatric Patients with Type 2 Diabetes Mellitus)
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 08 Aug 2021
Price :
$35
*
At a glance
- Drugs Metformin/sitagliptin (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 29 Jun 2021 Results of a pooled analysis comparing the characteristics of younger (Y, 10-14 yrs) vs. older (O, 15-17 yrs) patients in global clinical trials of sitagliptin as initial oral therapy (IOT, NCT01485614) or as add-on to metformin therapy (AMT, NCT01472367, NCT01760447). presented at the 81st Annual Scientific Sessions of the American Diabetes Association
- 07 Jan 2020 This trial has been completed in United kingdom.
- 10 Sep 2018 Planned number of patients changed from 240 to 140.